【摘要】：目的肺癌的局部淋巴結(jié)微轉(zhuǎn)移是肺癌患者術(shù)后復(fù)發(fā)的重要原因。本研究探討葡萄糖調(diào)節(jié)蛋白94(glucose regulated protein 94,GRP94)和非小細(xì)胞肺癌(non-small cell lung cancer,NSCLC)之間的聯(lián)系及GRP94在Ⅰ期NSCLC患者淋巴結(jié)中表達(dá)情況與患者預(yù)后的相關(guān)性,為患者的術(shù)后治療提供理論依據(jù)。方法采用免疫組化(immunohistochemical,IHC)法檢驗(yàn)2011-02-01-2014-01-31佳木斯大學(xué)附屬第一醫(yī)院胸外科54例Ⅰ期NSCLC組織及10例肺良性病變患者正常肺組織GRP94的表達(dá);IHC法檢驗(yàn)所選54例Ⅰ期的NSCLC患者及10例肺良性病變患者的肺門(N1)淋巴結(jié)、隆突下(N2)淋巴結(jié)中GRP94表達(dá)情況;隨訪所選54例患者預(yù)后(無癌生存時(shí)間)。結(jié)果54例患者癌組織中GRP94陽性表達(dá)率為100%(54/54),10例正常肺組織中無GRP94表達(dá),差異有統(tǒng)計(jì)學(xué)意義,χ~2=56.640,P0.001。108枚肺癌患者淋巴結(jié)中有22枚GRP94表達(dá)陽性,20枚正常淋巴中GRP94未見表達(dá),差異有統(tǒng)計(jì)學(xué)意義,χ~2=3.593,P=0.058。8例N1淋巴結(jié)GRP94陽性表達(dá)患者與36例淋巴結(jié)中未見GRP94表達(dá)患者生存曲線對比,差異無統(tǒng)計(jì)學(xué)意義,χ~2=0.264,P=0.608。6例N2淋巴結(jié)GRP94陽性表達(dá)患者與36例淋巴結(jié)中未見GRP94表達(dá),患者生存曲線對比,差異有統(tǒng)計(jì)學(xué)意義,χ~2=7.282,P=0.007。多因素分析顯示,N2淋巴結(jié)微轉(zhuǎn)移是Ⅰ期NSCLC患者預(yù)后不良危險(xiǎn)因素,P=0.008。結(jié)論 GRP94與肺癌的發(fā)生發(fā)展具有一定的相關(guān)性,N2淋巴結(jié)微轉(zhuǎn)移的患者對比不存在N2淋巴結(jié)微轉(zhuǎn)移的患者,生存率顯著降低。N2淋巴結(jié)微轉(zhuǎn)移是Ⅰ期NSCLC患者預(yù)后較差危險(xiǎn)因素。
[Abstract]:Objective Local lymph node micrometastasis of lung cancer is an important cause of postoperative recurrence of lung cancer. The aim of this study was to investigate the relationship between glucose regulated protein 94 (glucose regulated protein 94, GRP94 and non small cell lung cancer (non-small cell lung cancer,NSCLC) and the correlation between the expression of GRP94 in lymph nodes of patients with stage I NSCLC and prognosis. It provides a theoretical basis for the postoperative treatment of patients. Methods Immunohistochemical (immunohistochemical,IHC) method was used to detect the expression of GRP94 in 54 cases of stage I NSCLC and 10 cases of normal lung tissue in the first affiliated Hospital of Jiamusi University. IHC method was used to detect the expression of GRP94 in hilar (N1) lymph nodes and subprotruding (N2) lymph nodes in 54 patients with stage I NSCLC and 10 patients with benign pulmonary lesions, and the prognosis (cancer-free survival time) of 54 patients was followed up. Results the positive expression rate of GRP94 was 100% (54 鈮，

本文編號：2477460